TARRYTOWN, N.Y. and
PARSIPPANY, N.J., June 6, 2018 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ:REGN) and Zoetis Inc. (NYSE:ZTS)
today announced a five-year collaboration to research the use of
Regeneron's monoclonal antibody therapeutics in animals and
discover new veterinary treatments.
Under the terms of the agreement, Regeneron has granted Zoetis a
license for its VelocImmune® antibody technology,
which Zoetis will use to develop monoclonal antibodies modified for
species-specific use in companion and livestock animals. In
particular, Zoetis is exploring treatments for animals with
allergic and immune-related conditions, pain, inflammatory disease
and cancer. VelocImmune is Regeneron's proprietary
technology in which the immune system of mice is genetically
humanized, enabling the creation of fully-human and optimized
antibody drug candidates. Regeneron will receive a license fee,
approval and sales milestone payments and royalties on any
potential veterinary treatments.
"Regeneron's VelociSuite® drug discovery and
development platforms have produced many important new medicines
for people with serious medical conditions," said Drew Murphy, Ph.D., Senior Vice President of
Research at Regeneron. "This collaboration extends these valuable
tools to the development of monoclonal antibodies modified for
species-specific use in animals, an area we would not be exploring
otherwise, and provides us with more information to develop safe
and efficacious medicines for humans. We look forward to pairing
our antibody expertise with Zoetis' leadership in animal
health."
Regeneron will also select antibodies from its pipeline for
Zoetis to evaluate in dogs and cats that have certain
naturally-occurring diseases, such as osteoarthritis. Data
generated using this approach can help Regeneron predict whether a
pipeline therapeutic will demonstrate efficacy and safety in later
human trials, in addition to providing valuable information for
potential new veterinary therapeutics. Zoetis has been building
expertise in its own portfolio of monoclonal antibodies for
veterinary use, including the first antibody approved in the U.S.
and international markets to control the clinical signs of atopic
dermatitis in dogs.
"Regeneron and Zoetis share a similar passion for translating
scientific insights into groundbreaking medicines," said Dr.
Catherine Knupp, Executive Vice
President and President, Research and Development at Zoetis. "We
see significant advantages from Zoetis and Regeneron scientists
sharing knowledge and know-how across animal and human health. This
collaboration will enhance our internally-developed pipeline of
novel monoclonal antibodies and hasten the development of
therapeutics that could transform the way veterinarians treat a
range of diseases in animals."
About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading biotechnology
company that invents life-transforming medicines for people with
serious diseases. Founded and led by physician-scientists for 30
years, our unique ability to repeatedly and consistently translate
science into medicine has led to six FDA-approved treatments and
over a dozen product candidates, all of which were homegrown in our
laboratories. Our medicines and pipeline are designed to help
patients with eye disease, heart disease, allergic and inflammatory
diseases, pain, cancer, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through its
proprietaryVelociSuite® technologies,
including VelocImmune® to yield
optimized fully-human antibodies, and ambitious initiatives such as
the Regeneron Genetics Center, one of the largest genetics
sequencing efforts in the world.
For additional information about the company, please
visit www.regeneron.com or follow @Regeneron on
Twitter.
About Zoetis
Zoetis is the leading animal health company, dedicated to
supporting its customers and their businesses. Building on more
than 60 years of experience in animal health, Zoetis discovers,
develops, manufactures and markets veterinary vaccines and
medicines, complemented by diagnostic products, genetic tests,
biodevices and a range of services. Zoetis serves veterinarians,
livestock producers and people who raise and care for farm and
companion animals with sales of its products in more than 100
countries. In 2017, the company generated annual revenue of
$5.3 billion with approximately 9,000
employees. For more information, visit www.zoetis.com.
Regeneron Forward-Looking Statements and Use of Digital
Media
This news release includes forward-looking statements that
involve risks and uncertainties relating to future events and the
future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron"
or the "Company"), and actual events or results may differ
materially from these forward-looking statements. Words such as
"anticipate," "expect," "intend," "plan," "believe," "seek,"
"estimate," variations of such words, and similar expressions are
intended to identify such forward-looking statements, although not
all forward-looking statements contain these identifying words.
These statements concern, and these risks and uncertainties
include, among others, the nature, timing, and possible success and
therapeutic applications of Regeneron's products, product
candidates, and research and clinical programs now underway or
planned; the likelihood, timing, and scope of possible regulatory
approval and commercial launch of Regeneron's late-stage product
candidates and new indications for marketed products; the extent to
which the results from the research and development programs
conducted by Regeneron or its collaborators may be replicated in
subsequent studies and lead to therapeutic applications; the
potential for any license or collaboration agreement, including
Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical
Industries Ltd. (or their respective affiliated companies, as
applicable), as well as Regeneron's collaboration with Zoetis Inc.
discussed in this news release, to be cancelled or terminated
without any product success; unforeseen safety issues and possible
liability resulting from the administration of products and product
candidates in patients; serious complications or side effects in
connection with the use of Regeneron's products and product
candidates in clinical trials; coverage and reimbursement
determinations by third-party payers, including Medicare, Medicaid,
and pharmacy benefit management companies; ongoing regulatory
obligations and oversight impacting Regeneron's marketed products,
research and clinical programs, and business, including those
relating to the enrollment, completion, and meeting of the relevant
endpoints of post-approval studies; determinations by regulatory
and administrative governmental authorities which may delay or
restrict Regeneron's ability to continue to develop or
commercialize Regeneron's products and product candidates;
competing drugs and product candidates that may be superior to
Regeneron's products and product candidates; uncertainty of market
acceptance and commercial success of Regeneron's products and
product candidates and the impact of studies (whether conducted by
Regeneron or others and whether mandated or voluntary) on the
commercial success of Regeneron's products and product candidates;
the ability of Regeneron to manufacture and manage supply chains
for multiple products and product candidates; unanticipated
expenses; the costs of developing, producing, and selling products;
the ability of Regeneron to meet any of its financial projections
or guidance and changes to the assumptions underlying those
projections or guidance; and risks associated with intellectual
property of other parties and pending or future litigation relating
thereto, including without limitation the patent litigation
proceedings relating to Praluent® (alirocumab)
Injection, the ultimate outcome of any such litigation proceedings,
and the impact any of the foregoing may have on Regeneron's
business, prospects, operating results, and financial condition. A
more complete description of these and other material risks can be
found in Regeneron's filings with the United States Securities and
Exchange Commission, including its Form 10-K for the year ended
December 31, 2017 and its Form 10-Q
for the quarterly period ended March 31,
2018. Any forward-looking statements are made based on
management's current beliefs and judgment, and the reader is
cautioned not to rely on any forward-looking statements made by
Regeneron. Regeneron does not undertake any obligation to update
publicly any forward-looking statement, including without
limitation any financial projection or guidance, whether as a
result of new information, future events, or otherwise.
Regeneron uses its media and investor relations website and
social media outlets to publish important information about the
Company, including information that may be deemed material to
investors. Financial and other information about Regeneron is
routinely posted and is accessible on Regeneron's media and
investor relations website (http://newsroom.regeneron.com) and its
Twitter feed (http://twitter.com/regeneron).
Zoetis Forward-Looking Statements
This press release contains forward-looking statements, which
reflect the current views of Zoetis with respect to business plans
or prospects, expectations regarding products, the development of
future products and other future events. These statements are not
guarantees of future performance or actions. Forward-looking
statements are subject to risks and uncertainties. If one or more
of these risks or uncertainties materialize, or if management's
underlying assumptions prove to be incorrect, actual results may
differ materially from those contemplated by a forward-looking
statement. Forward-looking statements speak only as of the date on
which they are made. Zoetis expressly disclaims any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events or otherwise. A further list
and description of risks, uncertainties and other matters can
be found in our Annual Report on Form 10-K for the
fiscal year ended December 31, 2017,
including in the sections thereof captioned "Forward-Looking
Statements and Factors That May Affect Future Results" and "Item
1A. Risk Factors," in our Quarterly Reports on Form 10-Q and in our
Current Reports on Form 8-K. These filings and subsequent filings
are available online
at www.sec.gov, www.zoetis.com,
or on request from Zoetis.
Zoetis Investor Contact
Steve Frank
Tel: +1 (973) 822-7141
steve.frank@zoetis.com
Zoetis Media Contact
Elinore
White
Tel: +1 (973) 443-2835
elinore.y.white@zoetis.com
Regeneron Investor Relations
Manisha Narasimhan, Ph.D.
Tel: +1 (914) 847-5126
Manisha.narasimhan@regeneron.com
Regeneron Media Relations
Alexandra Bowie
Tel: +1
(914) 847-3407
alexandra.bowie@regeneron.com
View original
content:http://www.prnewswire.com/news-releases/regeneron-and-zoetis-announce-collaboration-to-research-antibody-therapies-for-use-in-animal-health-300660425.html
SOURCE Regeneron Pharmaceuticals, Inc.